Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy
Molecular Therapy · 2023-03 · 31 (3) · 616-630
DOI: 10.1016/j.ymthe.2023.01.010 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Therapy, 2023-03. Verfasst von Martin Schulz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer, 235 East 42nd Street, New York, NY 10017, USA. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, Dependovirus. Die Arbeit wurde bisher 133-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Assessment of anti-adeno-associated virus (AAV) antibodies in patients prior to systemic gene therapy administration is an important consideration regarding efficacy and safety of the therapy. Approximately 30%-60% of individuals have pre-existing anti-AAV antibodies. Seroprevalence is impacted by multiple factors, including geography, age, capsid serotype, and assay type. Anti-AAV antibody assays typically measure (1) transduction inhibition by detecting the neutralizing capacity of antibodies and non-antibody neutralizing factors, or (2) total anti-capsid binding antibodies, regardless of neutralizing activity. Presently, there is a paucity of head-to-head data and standardized approaches associating assay results with clinical outcomes. In addition, establishing clinically relevant screening titer cutoffs is complex. Thus, meaningful comparisons across assays are nearly impossible. Although complex, establishing screening assays in routine clinical practice to identify patients with antibody levels that may impact favorable treatment outcomes is achievable for both transduction inhibition and total antibody assays. Formal regulatory approval of such assays as companion diagnostic tests will confirm their suitability for specific recombinant AAV gene therapies. This review covers current approaches to measure anti-AAV antibodies in patient plasma or serum, their potential impact on therapeutic safety and efficacy, and investigative strategies to mitigate the effects of pre-existing anti-AAV antibodies in patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pfizer, 235 East 42nd Street, New York, NY 10017, USA.
- Labcorp-Monogram Biosciences, South San Francisco, CA 94080, USA.
- Pfizer, 235 East 42nd Street, New York, NY 10017, USA. Electronic address: suryanarayan.somanathan@pfizer.com.
- University of Florida, 1600 SW Archer Road, Gainesville, FL 32610, USA. Electronic address: barry.byrne@ufl.edu.
Förderung
- Pfizer
Zitieren
APA
Schulz, M., Levy, D. I., Petropoulos, C. J., Bashirians, G., Winburn, I., Mahn, M., Somanathan, S., Cheng, S. H., & Byrne, B. J. (2023). Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy. Molecular Therapy, 31(3), 616-630. https://doi.org/10.1016/j.ymthe.2023.01.010
Vancouver
Schulz M, Levy DI, Petropoulos CJ, Bashirians G, Winburn I, Mahn M, et al. Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy. Molecular Therapy. 2023;31(3):616-630. doi:10.1016/j.ymthe.2023.01.010
BibTeX
@article{Schulz2023,
author = {Schulz, Martin and Levy, Daniel I and Petropoulos, Christos J and Bashirians, George and Winburn, Ian and Mahn, Matthias and Somanathan, Suryanarayan and Cheng, Seng H and Byrne, Barry J},
title = {Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy},
journal = {Molecular Therapy},
year = {2023},
volume = {31},
number = {3},
pages = {616--630},
doi = {10.1016/j.ymthe.2023.01.010}
}
EUVIMED